Bristol-Myers Squibb Deal Provides PDL with Much Needed Boost
By Helen Scrutton
Pharma Deals Review: Vol 2008 Issue 99 (Table of Contents)
Published: 19 Aug-2008
DOI: 10.3833/pdr.v2008.i99.144 ISSN: 1756-7874
Section: Licensing
Fulltext:
Abstract
PDL BioPharma, a biotech that’s recently been forced to sell a number of its key assets, has announced some positive news in the form of a deal with Bristol-Myers Squibb for PDL’s Phase I multiple myeloma candidate, elotuzumab...
This page is available to subscribers only.
Not a subscriber? Join here
Already Registered? Please login using the top left purple box.
Copyright: © IQVIA 2018
RSS